22nd Jul 2015 06:21
LONDON (Alliance News) - Astrazeneca PLC said Wednesday that its phase III study of selumetinib in combination with dacarbazine for metastatic uveal melanoma did not meet its primary endpoint of progression free survival.
The company is undertaking a full evaluation of the data of the trial.
Selumetinib is also being investigated in a phase III study of differentiated thyroid cancer and a phase II study for neurofibromatosis Type 1.
The company said that the findings of this trial "have no impact" on the other studies.
The company said that the combination showed an adverse event profile "generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib."
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca